We performed a postmarketing surveillance study to determine the efficacy and safety of the oral quinolone antibacterial agent garenoxacin (Geninax ® Tablets 200 mg) against atypical pneumonia.
Text (1) Introduction
Garenoxacin (GRNX) is an oral quinolone antibiotic manufactured by Toyama Chemical Co., Ltd. (Tokyo, Japan); the company obtained approval for manufacturing and marketing this medication in July 2007 under the product name Geninax ® Tablets 200 mg. GRNX has a novel and unique chemical structure with lack of fluorine atom at the 6-position of the quinolone skeleton, which is normally considered essential to the antibacterial activity of conventional fluoroquinolones. GRNX shows excellent antibacterial activity against major bacterial pathogens in respiratory and otorhinolaryngological infections by inhibiting type II topoisomerases (DNA gyrase and topoisomerase IV), which are involved in bacterial DNA replication. In addition, GRNX shows strong antibacterial activity against penicillin-resistant Streptococcus pneumoniae, the increasing prevalence of which in the recent years has become a cause of concern [1, 2]. Further, because this drug shows a large AUC [3] and good tissue penetration [4, 5] after administration of a single dose of 400 mg/day, plasma concentrations in excess of the mutant prevention concentration for S. pneumoniae and Staphylococcus aureus were obtained for more than 24 h. Thus, GRNX is expected to prevent the emergence of drug-resistant strains [6] . Additionally, the antibacterial activity of GRNX against Chlamydophila pneumoniae and Mycoplasma pneumoniae associated with atypical pneumonia is stronger than that of existing fluoroquinolones and is comparable to that of macrolides [2] .
The Phase II and Phase III clinical trials performed in Japan to investigate the clinical efficacy of GRNX on atypical pneumonia [7, 8] showed that the efficacy rates in mycoplasma pneumonia and chlamydia pneumonia were 100% (22/22 patients) and 92.3% (12/13 patients), respectively. However, data on the efficacy of GRNX against these strains were not obtained from a sufficient number of patients at the time of development; therefore, active postmarketing data collection was indicated at the time of approval.
In this study, we performed a specified postmarketing surveillance study to confirm the efficacy and safety of GRNX against atypical pneumonia in daily clinical practice.
(2) Patients and methods
(2)-1 Target patients
The subjects were patients treated at 26 medical institutions across Japan between October 2009 and July 2011 who met the following inclusion criteria and to whom the exclusion criteria did not apply ( Table 1) .
The inclusion criteria were as follows:
1. Patients who were 15 years old or older 2. Patients who had a negative result in S. pneumoniae urinary antigen test 3. Patients who were differentiated as having suspected atypical pneumonia (Table   2 ) according to the Japanese Respiratory Society Guidelines for the Management of Community-Acquired Pneumonia in Adults (the JRS Guidelines) [9] Atypical pneumonia suspected Using criteria 1 to 5 on GRNX was administered under the approved regimen, and the administration period, concomitant drugs and combination therapies were not limited.
The observation period was until the termination of GRNX therapy. However, serological tests were adopted until 21 days after GRNX therapy for the termination of GRNX therapy. Adverse events were monitored until 4 days after GRNX therapy was terminated.
(2)-3 Efficacy evaluation
Clinical efficacy was assessed at the termination of GRNX therapy and was classified as "effective," "ineffective," or "evaluation not possible" according to clinical efficacy criteria [10] (Table 4 ). In patients receiving GRNX for 10 days or more, an additional assessment was made on the 10 th day after initiation of GRNX.
Safety was evaluated on the basis of the occurrence of adverse drug reactions. Adverse drug reactions were any events which a causal relationship with GRNX could not be denied during the observation period, such as medically unfavorable and unintended signs and symptoms (e.g., abnormal changes in laboratory tests and clinical symptoms and signs). Exacerbation of the pneumonia because of insufficient response to GRNX was not included.
(2)-4 Assessment of judgment/totalization results
An evaluation committee was formed with 5 members (one principal investigator, three coordinating investigators, and a representative physician), to discuss whether to include the problem cases, the handling of data in cases that deviated from the protocol, the handling of bacterial pathogens, and causal relationship between adverse events and GRNX therapy.
The term "bacterial pathogens" referred to bacteria that were detected at a score of ≥3+ (the level of ≥10 5 colony-forming units/ml) derived from sputum. S. pneumoniae and Haemophilus influenzae detected at a clear level were classified as bacterial pathogens. Positive Mycoplasma pneumoniae rapid diagnosis results and positive C.
pneumoniae and M. pneumoniae serological test results were also obtained to detect bacterial pathogens.
Adverse drug reactions were analyzed using the Medical Dictionary for Regulatory Activities, Japanese version (MedDRA/J, ver. 15.0).
(2)-5 Analysis sets
Efficacy was evaluated in the patients in the efficacy analysis set, which included patients from whom survey forms were collected and who met the inclusion and exclusion criteria and who received GRNX under the approved regimen. The safety was evaluated in the patients in the safety analysis set from whom survey forms were collected and who received GRNX at least one time.
(2)-6 Statistical analysis
Statistical analysis was performed using χ 2 test for comparison, and when the expected values were 5 or less, Fisher's exact probability test was employed.
(3) Results

(3)-1 Analysis sets and patient characteristics
The analysis sets are shown in Figure 1 .
Of the 105 patients from whom the survey forms were collected, all patients were included in the safety analysis set. From the safety analysis set, 71 patients were selected for the efficacy analysis set. From the efficacy analysis set, 21 patients were selected for the bacterial pathogens detection set. Table 5 shows the implementation status of bacteriological examination, rapid The patient characteristics of efficacy and safety analysis sets are shown in Table 6 .
Among patients in the safety analysis set, 61.0% were female, 84.8% were non-elderly, 93.3% were outpatients, 87.6% had mild pneumonia according to the A-DROP scoring system, 87.6% had no underlying disease, and 84.8% were not receiving antibiotic treatment immediately before initiation of GRNX therapy. The average administration period was 8.4 ± 2.6 days, with the greatest number of patients at 3 to 7 days (51.4%), followed by 8 to 14 days (45.7%). Patient characteristics in the efficacy analysis set were almost same as those in the safety analysis set.
(3)-2 Clinical efficacy
In the efficacy analysis set (suspected atypical pneumonia), the clinical efficacy findings at the time of the termination and the 10 th day of GRNX therapy are shown in Table 7 .
The efficacy rate of GRNX at the time of the termination of administration, excluding patients with an indeterminate result, was 94.8% (55/58 patients). The efficacy rate according to the severity of pneumonia using the A-DROP scoring system was 96.0% (48/50 patients) in those with mild pneumonia and 7/8 patients in those with moderate pneumonia. The efficacy rate according to the length of GRNX administration period was 89.5% (17/19 patients) for an administration period of 6-7 days, 100% (21/21 patients) for 8-10 days, and 100% (10/10 patients) for 11-14 days, respectively. In addition, the efficacy rate in patients who received GRNX for 10 days or more and in whom clinical efficacy was evaluated at the 10 th day after initiation of GRNX therapy was 100% (16/16 patients), which was similar to the efficacy rate at the termination of GRNX therapy.
In the 10 patients who received antibiotic treatment prior to GRNX therapy (within 7 days before beginning administration), for whom antibiotics were ineffective or pneumonia recurred without the antibiotics taking effect, the efficacy rate of GRNX was 100% (10/10 patients). The antibiotics taken before initiation of GRNX therapy were as follows: cefcapene pivoxil (CFPN-PI) in 4 patients; clarithromycin (CAM) in 3 patients;
and cefditoren pivoxil (CDTR-PI), azithromycin, and levofloxacin (LVFX) in 1 patient each. All of these antibiotic treatments were oral medications. In these 10 patients, the prior antibiotic treatment was considered to be ineffective after 2 to 8 days of administration and they received GRNX. The bacterial pathogens were detected in 5 of The clinical efficacy in patients with a definitive diagnosis of atypical pneumonia is shown in Table 8 . 
(3)-3 Adverse drug reactions
Overall, 7 adverse drug reactions related with GRNX were observed in 5 non-elderly patients, and the incidence of adverse drug reaction was 4.8% (5/105 patients) ( Table 9 ).
Adverse drug reactions included upper abdominal pain in 1 patient, diarrhoea in 1 patient, rash in 1 patient, concurrent gastroenteritis and headache in 1 patient, and concurrent diarrhoea and vomiting in 1 patient. In the patient who presented with concurrent gastroenteritis and headache, GRNX therapy was discontinued; these symptoms disappeared 2-3 days after discontinuing GRNX therapy. No serious adverse drug reactions were observed. The incidences of adverse drug reactions according to the MedDRA/J system organ class were as follows: gastrointestinal disorders in 2.9% of patients (3 patients); infections and infestations in 1.0% (1 patient); nervous system disorders in 1.0% (1 patient); and skin and subcutaneous tissue disorders in 1.0% (1 patient).
(4) Discussion
In the present study, we examined the usefulness of GRNX for treatment of atypical pneumonia in daily clinical practice. The clinical efficacy (efficacy rate) for 71 patients with suspected atypical pneumonia at the time of termination of GRNX therapy was 94.8% (55/58 patients). These patients included 14 patients with a definitive diagnosis of atypical pneumonia; the efficacy rate in these patients was 92.3% (12/13 patients) . In this study, we found that the efficacy of GRNX when used in daily clinical practice was similar to those in other clinical studies [7, 8] .
In this study, we made an effort to exclude patients with bacterial pneumonia by excluding patients with a positive result in the S. pneumoniae urinary antigen test at the initiation of GRNX therapy. However, patients in the efficacy analysis set included 8 patients with a definitive diagnosis of bacterial pneumonia and 2 with a definitive diagnosis of mixed infection. The JRS Guidelines [9] state that in differentiation of disease types, a firm differentiation of atypical pneumonia alone is difficult. Our findings were consistent with those described in the above guidelines.
The efficacy rate of GRNX was 100% (10/10 patients) in patients for whom treatment with oral antimicrobial agents (e.g., CFPN-PI, CAM, and CDTR-PI) within 1 week of GRNX therapy was ineffective (or in whom pneumonia recurred without the agents taking effect). This efficacy rate was comparable to that of 93.8% (45/48 patients) in patients who did not receive antibiotic treatment before GRNX therapy. Antimicrobial agents used before GRNX therapy included quinolones in 1 patient, macrolides in 4 patients, and cephems in 5 patients. In 5 of these patients, M. pneumoniae and H. influenzae were detected as the causative agents. GRNX has potent antibacterial activity against M. pneumoniae (MIC90, 0.0313 μg/ml) and H. influenzae (MIC90, 0.05 μg/ml) [2] . We considered that the efficacy rate of GRNX in this study reflected the antibacterial activity. In patients for whom antibiotic treatment was ineffective, the efficacy of GRNX could be confirmed in clinical practice.
Among patients with moderate pneumonia as assessed by the A-DROP scoring system, GRNX was effective in 7/8 patients. Of the 7 patients in whom GRNX was effective, 4
were elderly patients aged 76-81 years. In addition, all 9 patients with underlying diseases had bronchial asthma, which is a chronic respiratory disease; GRNX was effective in all these 9 patients. Thus, GRNX can be effective even in patients suspected with atypical pneumonia who possess the above-mentioned characteristics that reduce the efficacy of GRNX.
A postmarketing surveillance performed in Japan [11] on a single daily administration of 500 mg of LVFX, an orally administered quinolone antimicrobial agent (like GRNX), which is effective against M. pneumoniae and C. pneumoniae, showed that LVFX was effective against M. pneumoniae and C. pneumoniae in 2/2 patients and 9/9 patients, respectively. In addition, a specific postmarketing surveillance of CAM [12, 13] , which is a macrolide antibiotic recommended as an empiric treatment for outpatients with suspected atypical pneumonia in the JRS Guidelines [9] , showed that the efficacy rates in patients infected with M. pneumoniae, C. pneumoniae, M. pneumoniae + C. pneumoniae, and those suspected with atypical pneumonia were 96.8% (153/158 patients), 92.9% (78/84), 98.3% (57/58), and 96.3% (105/109), respectively. Despite the small number of patients in our study, our results showed that GRNX had the same efficacy as that of LVFX and CAM.
Of 8 patients diagnosed with M. pneumoniae single-strain infection, 5 were diagnosed by using ImmunoCard ® . ImmunoCard ® is widely used in daily clinical practice, because it is rapid and easy to use. The frequency of use of ImmunoCard ® in this study reflected that in daily clinical practice. However, Beersma et al. pointed out that ImmunoCard ® may be inaccurate for the detection of M. pneumoniae [14] . We should consider using ImmunoCard ® in combination with paired serum specimens or other diagnostic techniques to make a definitive diagnosis of M. pneumoniae infection.
GRNX was considered to be ineffective in 3 patients when the administration was terminated. One patient was an elderly person who was suspected of having mild atypical pneumonia. The patient had complicating cerebrovascular disorder sequelae, and showed mild chest radiograph shadows and marked coughing and inflammatory response (C-reactive protein [CRP] level, 4.26 mg/dl); however, the bacterial pathogen could not be identified. In this case, GRNX therapy may have been ineffective because of aspiration pneumonia due to cerebrovascular disorder sequelae. The second patient was an elderly patient with a moderate mixed infection of S. pneumoniae detected in a bacteriological examination and was positive for mycoplasma in rapid diagnosis before initiation of GRNX therapy. Although the fever and symptoms showed a tendency to improve on the third day of GRNX administration, the agent was changed in accordance with the patient's wishes; therefore, GRNX was considered to be ineffective. The third patient's condition was diagnosed as mild suspected atypical pneumonia before initiation of GRNX therapy. Fever, chest pain, and pleural effusion were observed. However, the bacterial pathogen could not be identified in rapid diagnosis, a bacteriological examination, or measurement of serum antibody titer. GRNX was considered to be ineffective because of a diagnosis of pyothorax on the 6 th day of administration.
GRNX was administered for 10 days or more in 18 patients in the efficacy analysis set.
GRNX was considered to be effective in 16 of these patients on the 10 th day after initiation of administration, and thus administration was continued. Further examination about appropriate administration duration was considered necessary to ascertain when administration should be discontinued.
The incidence of adverse drug reactions was 4.8% (5/105 patients). No unique adverse reactions to GRNX were observed; therefore, the safety of GRNX was not viewed as a problem deserving special mention.
In conclusion, GRNX may be used in outpatient treatment in daily clinical practice not only in patients with mild to moderate atypical pneumonia caused by M. pneumoniae and C. pneumoniae infection but also in patients suspected of having atypical pneumonia in which the pathogen cannot be identified. Thus, further studies using a large number of patients should be performed in the future.
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Effective
Of the conditions (1) to (3) below, if the following items are met; condition (1) fulfills its condition; either condition (2) or (3) satisfies these conditions; and remaining condition does not lead to exacerbation, it is classified as "effective."
(1) Improvement or disappearance of the symptoms and signs of pneumonia A determination of maximum body temperature, cough, sputum (amount, properties), dyspnea, chest pain, or chest rales. (a) Improvement in the symptoms and signs of 1 item or more.
(b) In cases of fever at the initiation of administration (or registered), the fever must improve. If the fever declines after the initiation of administration (or registered), even if body temperature is 37.0°C or more, it will be treated as an improvement. (2) If all abnormalities in chest X-ray shadows improve or disappear Determined on the basis of the density and spread of the chest X-ray shadow.
(3) Improvement or disappearance of inflammation
No exacerbated items and if the following 2 items are met, "Improvements to 9000/μl or less of the peripheral blood white blood cell count" or "Decline from the highest value of CRP." The change within the range of normal level is not considered.
Ineffective
If the above criteria are not "effective," the case is determined to be "ineffective."
Evaluation not possible If it is not possible to determine either "effective" or "ineffective," it is classified as "evaluation not possible." 16 The number of patients for included or excluded each analysis set.
Figure legends
Patients placed " a " exclude those who were positive in the rapid diagnosis/serological test.
Figure 2
The number of patients categorized by bacterial pathogens in the efficacy analysis set.
These categories are atypical pneumonia, bacterial pneumonia, and bacterial pathogen indeterminate. 
